Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) and Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.
Valuation and Earnings
This table compares Biorestorative Therapies and Protagonist Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biorestorative Therapies | $357,870.00 | 15.66 | -$14.24 million | ($1.07) | -0.21 |
| Protagonist Therapeutics | $281.99 million | 36.40 | -$130.15 million | $1.03 | 154.00 |
Risk & Volatility
Biorestorative Therapies has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500.
Institutional and Insider Ownership
69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Biorestorative Therapies and Protagonist Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biorestorative Therapies | -3,088.27% | -508.42% | -230.94% |
| Protagonist Therapeutics | 29.40% | 12.03% | 11.23% |
Analyst Recommendations
This is a breakdown of recent ratings for Biorestorative Therapies and Protagonist Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biorestorative Therapies | 1 | 0 | 0 | 0 | 1.00 |
| Protagonist Therapeutics | 0 | 2 | 15 | 1 | 2.94 |
Protagonist Therapeutics has a consensus target price of $140.53, indicating a potential downside of 11.40%. Given Protagonist Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Biorestorative Therapies.
Summary
Protagonist Therapeutics beats Biorestorative Therapies on 13 of the 15 factors compared between the two stocks.
About Biorestorative Therapies
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Receive News & Ratings for Biorestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biorestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
